v3.25.2
Share-Based Compensation (Tables) - Sonnet BioTherapeutics Holdings, Inc. [Member]
12 Months Ended
Jul. 02, 2025
Sep. 30, 2024
Schedule of Share-based Compensation Expense

The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying unaudited interim consolidated statements of operations as follows:

                 
   Three Months Ended June 30,   Nine Months Ended June 30, 
   2025   2024   2025   2024 
Research and development  $   $28,268   $28,268   $81,089 
General and administrative       32,127    32,127    89,706 
Share-based compensation  $   $60,395   $60,395   $170,795 

The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying consolidated statements of operations as follows:

  

   2024   2023 
   Years ended September 30, 
   2024   2023 
Research and development  $109,356   $121,265 
General and administrative   121,834    127,361 
Share-based compensation  $231,190   $248,626 
Schedule of Restricted Stock Units Activity

The following table summarizes RSU activity under the Plan:

       Weighted 
       Average Grant 
   RSU   Date Fair Value 
Unvested balance at October 1, 2024   9,175   $14.08 
Vested   (9,175)  $14.08 
Unvested balance at June 30, 2025      $ 

The following table summarizes RSU activity under the Plan:

  

       Weighted 
       Average Grant 
   RSU   Date Fair Value 
Unvested balance at October 1, 2022   266   $1,507.76 
Granted   976   $171.77 
Vested   (266)  $1,507.76 
Forfeited   (688)  $170.72 
Unvested balance at September 30, 2023   288   $174.26 
Granted   9,175   $14.08 
Vested   (288)  $174.26 
Forfeited      $ 
Unvested balance at September 30, 2024   9,175   $14.08 
Schedule of Restricted Stock Awards Activity

The following table summarizes RSA activity under the Plan:

       Weighted 
       Average Grant 
   RSA   Date Fair Value 
Unvested balance at October 1, 2024   7,977   $14.08 
Vested   (7,977)  $14.08 
Unvested balance at June 30, 2025      $ 

The following table summarizes RSA activity under the Plan:

  

       Weighted 
       Average Grant 
   RSA   Date Fair Value 
Unvested balance at October 1, 2022      $ 
Granted   688   $226.16 
Unvested balance at September 30, 2023   688   $226.16 
Granted   7,977   $14.08 
Vested   (688)  $226.16 
Unvested balance at September 30, 2024   7,977   $14.08